High tissue MMP14 expression predicts worse survival in gastric cancer, particularly with a low PROX1 by Kasurinen, Aaro et al.
Cancer Medicine. 2019;00:1–11.    | 1wileyonlinelibrary.com/journal/cam4
Received: 21 February 2019 | Revised: 17 July 2019 | Accepted: 11 September 2019
DOI: 10.1002/cam4.2576  
O R I G I N A L  R E S E A R C H
High tissue MMP14 expression predicts worse survival in gastric 
cancer, particularly with a low PROX1
Aaro Kasurinen1  |   Silvia Gramolelli1 |   Jaana Hagström2 |   Alli Laitinen1,3 |   
Arto Kokkola3 |   Yuichiro Miki4 |   Kaisa Lehti4,5 |   Masakazu Yashiro6 |    
Päivi M. Ojala1,7 |   Camilla Böckelman1,3 |   Caj Haglund1,3
1Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
2Department of Pathology and Oral Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
3Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
4Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden
5Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
6Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
7Section of Virology, Division of Infectious Diseases, Department of Medicine, Imperial College London, London, UK
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Camilla Böckelman and Caj Haglund contributed equally to this work. 
Correspondence
Aaro Kasurinen, Translational Cancer 
Medicine Research Program, Faculty of 




This study was financially supported by the 
Faculty of Medicine, University of Helsinki, 
Helsinki, Finland (CB), Competitive 
State Research Financing of the Expert 
Responsibility of Helsinki University 
Hospital, Helsinki, Finland (CH), the 
Finnish Cancer Foundation (CH, PMO, 
KL), Finska Läkaresällskapet (CH, CB), 
the Sigrid Jusélius Foundation (CH, AK, 
PMO), the Swedish Cancer Society (KL), 
a Center of Excellence grant (Translational 
Cancer Biology; PMO), and a postdoctoral 
researcher grant (SG) from the Academy of 
Finland. The funders played no role in the 
study design, data collection or analysis, the 
decision to publish, or in the preparation of 
the manuscript.
Abstract
Matrix metalloproteinase 14 (MMP14), a membrane‐associated matrix metallopro-
teinase, has been shown to influence the invasion and metastasis of several solid 
tumors. Prospero homeobox protein 1 (PROX1), involved in the development and 
cell fate determination, is also expressed in malignant diseases functioning either as 
a tumor‐suppressing or oncogenic factor. In certain cancers PROX1 appears to tran-
scriptionally suppress MMP14 expression. This study, therefore, aimed to explore 
the association between MMP14 and PROX1 and understand their potential as prog-
nostic biomarkers in gastric cancer. The cohort consisted of 313 individuals operated 
for gastric adenocarcinoma between 2000 and 2009 in the Department of Surgery, 
Helsinki University Hospital. MMP14 and PROX1 expressions were studied using 
immunohistochemistry in the patient sample and using immunoblotting and immu-
nofluorescence in gastric cancer cell lines. We generated survival curves using the 
Kaplan‐Meier method, determining significance via the log‐rank test. A high MMP14 
expression associated with being ≥67  years (P  =  .041), while a positive nuclear 
PROX1 expression associated with tumors of a diffuse histological type (P = .041) 
and a high cytoplasmic PROX1 expression (P  <  .001). Five‐year disease‐specific 
survival among patients with a high MMP14 expression was 35.9% (95% confidence 
interval [CI] 24.9‐46.9), compared to 45.3% (95% CI 38.0‐52.6) for patients with a 
low MMP14 (P = .030). Survival was worse specifically among those with a high
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1 |  INTRODUCTION
Gastric cancer is one of the most common malignancies 
worldwide, featuring a poor prognosis largely due to its late 
diagnosis. Molecular classifications of the disease, in addi-
tion to current histological classifications, are essential for 
predicting the disease's behavior, the further development of 
therapy, and individualizing treatment. The Cancer Genome 
Atlas project proposed a novel molecular subtype classifica-
tion, although it is not yet applicable for routine use.1,2
Matrix metalloproteinases (MMPs), a group of zinc‐con-
taining proteases expressed in a plethora of tissues, represent 
important contributors to metastasis due to their capabilities 
of degrading the extracellular matrix (ECM). Matrix metal-
loproteinases can also promote carcinogenesis by activating 
cell migration and oncogenic signaling pathways.3,4 Previous 
studies demonstrated that a high expression of MMPs associ-
ated with a poor patient prognosis, tumor invasion, and me-
tastasis in several cancers.5-10
Matrix metalloproteinase 14 (MMP14), a membrane‐an-
chored MMP, features strong ECM‐degrading capabilities. 
Furthermore, MMP14 expression appears to be higher in gastric 
cancer tissues compared to noncancerous mucosa, indicating a 
worse prognosis in cancer patients with a high MMP14 expres-
sion compared to patients with a low MMP14 expression.5,9-11
Prospero homeobox protein 1 (PROX1), a transcription factor 
related to organ development and cell fate determination,12-15 is 
also expressed in various cancers acting either as a tumor suppres-
sor or as an oncogene depending on the tumor type.16 In healthy 
gastric mucosa, miR‐489 inhibits PROX1 levels, while the loss 
of function mutations in gastric carcinogenesis directly results in 
increased PROX1 levels.17 Overexpression experiments involv-
ing miR‐489 resulted in the deceleration of growth and reduced 
PROX1 levels, suggesting that PROX1 may contribute to gastric 
carcinogenesis. However, a high immunohistochemical PROX1 
expression in gastric cancer patients' tissue samples has been par-
adoxically linked both to better and worse prognoses.18-20
A functional link between MMP14 and PROX1 was re-
cently established.21 The expression of PROX1 and MMP14 
was, however, inversely related in cell lines and murine mod-
els, and additional experiments demonstrated that PROX1 
directly inhibited the transcription of MMP14 by binding to 
its promoter region. Cellular mechanisms were investigated in 
several cell types, although not in gastric cancer cells.
Therefore, this study aimed to investigate the relationship 
between MMP14 and PROX1 in gastric cancer and to explore 
their values as prognostic biomarkers. We studied MMP14 
and PROX1 expression levels in tissue samples compared 
with clinical data, and determined the MMP14 and PROX1 
expression levels in gastric cancer cells.
2 |  MATERIALS AND METHODS
2.1 | Patients
The cohort consisted of 313 individual patients operated for his-
tologically verified gastric adenocarcinoma in the Department 
of Surgery, Helsinki University Hospital, between 2000 and 
2009. We excluded patients with a history of other malignant 
disease or synchronous cancer. The median age at the time of 
surgery was 67.4 years (interquartile range [IQR] 57.1‐76.5) 
and 161 patients (51.4%) were female. The seventh version of 
the tumor‐node‐metastasis classification (TNM)22 was used 
for cancer staging: 62 (19.8%) were stage I, 72 (23.0%) were 
stage II, 115 (36.7%) were stage III, and 63 (20.1%) were 
stage IV. A total gastrectomy was required for 153 patients 
(48.9%) and partial for 160 (51.1%); lymphadenectomy was 
performed according to D1 in 107 (34.2%) and D2 in 203 pa-
tients (64.9%). In 198 patients (63.3%), the disease was lymph 
node‐positive and 63 cases (20.1%) also presented with distant 
metastases. According to the Laurén classification,23 124 tu-
mors (39.6%) were of the intestinal histological type. Curative 
surgery was possible for 228 patients (72.8%). In addition, 15 
patients (4.8%) received neoadjuvant treatment and 125 pa-
tients (39.9%) received postoperative adjuvant treatment. The 
median follow‐up time was 2.3 years, with 66 patients (21.1%) 
still living at the end of follow‐up. Five‐year disease‐specific 
survival for the entire patient cohort was 43.3% (95% confi-
dence interval [CI] 37.4‐49.2).
Living data and causes of death until September 2017 
were acquired from patient records, the Population Register 
Center of Finland, and Statistics Finland.
The Surgical Ethics Committee of the Helsinki University 
Hospital (Dnro HUS 226/E6/06, extension TMK02 §66 
17.04.2013) approved the study and study protocol. Authorization 
to use tissue samples retrospectively without individual consent 
MMP14 and absent nuclear PROX1 expression (hazard ratio [HR] 1.65; 95% CI 
1.09‐2.51; P = .019). Thus, this study confirms that a high MMP14 expression predicts 
a worse survival in gastric cancer, revealing for the first time that survival is particularly 
worse when PROX1 is low.
K E Y W O R D S
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was granted by the National Supervisory Authority of Welfare 
and Health (Valvira Dnro 10041/06.01.03.01/2012).
2.2 | Sample preparation and 
immunohistochemistry
Original tumor samples were fixed in formalin, embed-
ded in paraffin, and stored at the Department of Pathology, 
University of Helsinki. Samples were collected from the ar-
chives and each was given an identification number, connect-
ing the sample to the clinical data and enabling anonymous 
analysis. In total, four 1.0‐mm cores were taken from each 
tumor sample and embedded in a new paraffin block using an 
automatic tissue microarray instrument (TMA Grand Master; 
3D Histech Ltd). Samples were subsequently cut and pro-
cessed in 4‐µm sections for immunohistochemistry.
The procedure was continued by fixation and drying of the 
slides (at 37°C for 12‐24 hours). Subsequently, sections were 
deparaffinized in xylene and rehydrated through lowering 
the concentrations of ethanol and distilled water. Slides were 
treated in a PT module (LabVision UK Ltd) in a Tris‐HCl 
buffer (pH 8.5) for 20 minutes at 98°C. Staining was carried 
out in an Autostainer 480 (LabVision) using the Dako REAL 
EnVision Detection System, Peroxidase/DAB+, Rabbit/Mouse 
(Dako). Next, the slides were incubated with a 0.3% Dako 
REAL Peroxidase‐Blocking Solution for 5 minutes to block the 
endogenous peroxidase activity. Then the samples were treated 
and incubated with a mouse monoclonal MMP14 antibody (di-
luted to 1:70 in a Dako REAL Antibody Diluent; Chemicon 
International, Inc) for 1 hour and with a peroxidase‐conjugated 
Dako REAL EnVision/HRP, Rabbit/Mouse reagent for 30 min-
utes. Visualization was completed using the Dako REAL 
DAB + Chromogen, and incubated for 10 minutes. Slides were 
counterstained using Meyer's hematoxylin, washed in tap water 
for 10 minutes, and mounted in Aquamount (BDH).
The same protocol was used for the PROX1 staining, ex-
cept for the detection kit (ImmPRESS HRP Polymer Detection 
Kit, Peroxidase, anti‐goat IgG; Vector Laboratories) and 
the antibody used (anti‐human Prox1 antibody, diluted to 
1:1800 = 18 µg/mL incubated overnight at room temperature 
[RT]; R&D Systems, Inc).18
2.3 | Scoring of immunoreactivities
In total, 278 tissue cores in the MMP14‐stained sam-
ples included cancer cells and were suitable for the in-
terpretation of MMP14 expression (Figure 1A). Matrix 
metalloproteinase 14 was distributed in the intracellular 
perinuclear cytoplasmic vesicles and diffusely on the can-
cer cells' plasma membrane. We quantified the MMP14 
expression by scoring the cancer cells' cytoplasmic stain-
ing intensity, where a score of 3 indicated strong staining, 
2 indicated moderate, 1 indicated weak, and 0 indicated 
absent staining. For the final analyses, the data were split 
in two, between a high expression (consisting of scores 2 
and 3) and a low expression (consisting of scores 0 and 1) 
group. In addition, 275 tissue cores in the PROX1‐stained 
samples were suitable for scoring the amount of PROX1 
positive nuclei (Figure 1B). PROX1 staining was observed 
in the cytoplasm and in the nucleus. PROX1‐stained sam-
ples were scored quantitatively for the number of cells 
harboring nuclear PROX1, where 4 represented over 75%, 
3 represented 50%‐75%, 2 represented 25%‐50%, 1 repre-
sented less than 25%, and 0 represented no reactivity in 
the nucleus. For the final analyses, the data were grouped 
into two categories: negative (consisting of samples with 
no nuclear PROX1 staining) and positive (consisting of 
samples with any nuclear PROX1 staining) groups. The 
highest score for the four tissue microarray cores per pa-
tient was chosen to represent the patient in the statisti-
cal analyses. All samples were scored by two researchers 
(AK and JH), who were blinded to the clinical data. Cases 
with any variance were re‐assessed and the final score was 
reached through consensus.
2.4 | Cell culture
We used 11 human gastric cancer cell lines: AGS (gastric 
adenocarcinoma), MKN‐28, MKN‐7, MKN‐74 (intesti-
nal‐type gastric adenocarcinoma), TMK‐1, OCUM‐2MD3, 
OCUM‐12, OCUM‐14, NUGC3, MKN‐45, and KATOIII 
F I G U R E  1  Representative images of the immunohistochemistry 
of gastric cancer tumors with (A) matrix metalloproteinase 14 
(MMP14) staining and (B) prospero homeobox protein 1 (PROX1) 
staining. Original magnification at 20×
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(diffuse‐type gastric adenocarcinoma).24-29 The KATOIII 
and MKN‐7 cell lines were purchased from the Japanese 
Collection of Research Bioresources' cell bank (JCRB 
Cell Bank, National Institutes of Biomedical Innovation, 
Health and Nutrition), the MKN‐28, TMK‐1, and AGS 
cell lines were kindly provided by Professor Ari Ristimäki 
(University of Helsinki), and Professor Masakazu Yashiro 
(Osaka City University Graduate School of Medicine) pro-
vided MKN‐74, MKN‐45, NUGC3, OCUM‐14, OCUM‐12, 
and OCUM‐2MD3 cell lines. The cells were grown in an 
RPMI‐1640 media supplemented with 10% fetal calf serum 
(Gibco), 1% L‐Glutamine, and 1% Pen Strep (Thermo Fisher 
Scientific). Cells were grown in standard conditions (37°C, 
5% CO2).
2.5 | Small interfering RNA transfection
AGS cells were plated at a density of 2 × 105 cells/mL. On 
the following day, the cells were transfected with either a 
control (12935200; Invitrogen) or two different PROX1‐tar-
geting small interfering RNAs (siRNAs) (Stealth RNAi™ 
targeting HSS 108596; HSS 108597; Invitrogen) using 
Lipofectamine RNAiMAX (Thermo Fisher Scientific) ac-
cording to the manufacturer's instructions. Two days after 
transfection, the cells were harvested and lysed for immu-
noblot analysis.
2.6 | Protein detection by 
immunofluorescence assay
AGS, TMK‐1, MKN28, and MKN7 cells were plated on cover 
slips in a 24‐well plate, with 105 cells placed in each well in 
500 µL of RPMI‐1640 media. Cells were fixed by cross‐link-
ing with 4% paraformaldehyde (diluted in phosphate buffered 
saline [PBS]), and incubated for 20 minutes at RT. Cells were 
permeabilized with 0.3% triton‐X (diluted in PBS) and simul-
taneously the nuclei were stained with Hoechst 1 µg/mL, incu-
bated for 10 minutes at RT, and washed with PBS. Blocking 
was completed by incubating the cover slips for 45 minutes at 
RT in 0.5% bovine serum albumin (BSA) in PBS. The primary 
antibodies used were rabbit anti‐PROX1 (ab199359, diluted to 
1:300 in 0.5% BSA in PBS; Abcam) and rabbit anti‐MMP14 
(ab51074, diluted to 1:100 in 0.5% BSA in PBS; Abcam). 
Cells were incubated for 1 hour in wet chambers at RT with 
the primary antibody, and subsequently washed with PBS. The 
secondary antibody used was goat anti‐rabbit Alexa Fluor 594‐
conjugated (diluted to 1:500 in 0.5% BSA in PBS). Incubation 
for 1  hour at RT took place in wet chambers. Finally, cells 
were washed with PBS and distilled water, then mounted on 
slides with Mowiol 4‐88 and incubated overnight at RT. Cover 
slips were imaged using the Sigma Panoramic FLASH II, 
3DHIstech‐Aldrich, 81381.
2.7 | Protein lysis and immunoblot
Cell pellets were produced by centrifuging 1 million cells 
of each cell line. The cells were treated with 200  µL of a 
radioimmunoprecipitation assay buffer (150 mmol/L NaCl, 
1% NP‐40, 0.5% Na‐deoxycholate, 0.1% sodium dodecyl sul-
fate, and 50 mmol/L Tris‐HCl pH 8.0), supplemented with 
the phosphatase (Pierce™ 88667) and protease (Pierce™ 
88666) inhibitors. Lysis was performed alternating 3  sec-
onds vortexing with 10 minutes on ice for a total of 30 min-
utes. Cell lysate was cleared by centrifugation (16  000  g, 
for 20 minutes at 4°C). Cell lysate was boiled for 10 min-
utes with SDS sample buffer and reducing agent and loaded 
onto Criterion TGX precast gels (Bio‐Rad). Gels were run 
for 45 minutes at 55 mA and transferred on to nitrocellulose 
membranes with the trans‐blot Turbo Transfer system (Bio‐
Rad). Blocking and antibody incubations were performed in 
a 5% nonfat milk, Tris‐buffered saline, and 0.01% tween‐100 
solution for 1 hour at RT. Membranes were incubated in a 
rabbit monoclonal anti‐PROX1 antibody (ab199359, diluted 
to 1:1000; Abcam) or a rabbit monoclonal anti‐MMP14 an-
tibody (ab51074, diluted to 1:1000; Abcam), and a mouse 
monoclonal anti‐beta‐actin antibody (sc‐47778, diluted to 
1:2500; Santa Cruz Biotechnology) or a mouse anti‐TBG1 
antibody (T6557; Sigma‐Aldrich) at 4°C overnight with gen-
tle rocking. After washing, membranes were incubated in the 
appropriate secondary antibody (anti‐rabbit HRP‐linked anti-
body (7074; CST) and the anti‐mouse HRP‐linked antibody 
(7076; CST) diluted to 1:2500. Chemiluminescent detec-
tion was carried out through a 1‐minute incubation with the 
WesternBright Sirius HRP substrate components mixed at 
1:1 (K‐12043‐D20; Advansta Corporation) at RT with gentle 
shuffling. The membrane was imaged in a Chemi Doc XRS+ 
(Bio‐Rad).
2.8 | Quantification of the immunoblot band 
intensities
The band intensities were quantified using the Fiji software 
program (https ://imagej.net/Fiji) and normalized to the cor-
responding loading control. The numbers below each blot 
indicate the relative band intensity compared to the control.
2.9 | Statistical analyses
We calculated the P values for associations and correlations 
between PROX1, MMP14, and clinicopathologic variables 
using the Pearson's chi‐squared test and the Spearman's 
rank correlation test. Survival curves were created using the 
Kaplan‐Meier method and the P values were determined 
based on the log‐rank test. The Cox proportional hazard 
model was applied to the univariate and multivariate survival 
analyses. Covariates entered into the multivariate survival 
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analyses consisted of age, cancer staging, the Laurén clas-
sification, and MMP14 expression. The cancer staging was 
processed as a categorical covariate. We found no significant 
interaction terms. Disease‐specific survival was calculated 
from the date of surgery until death due to gastric cancer. 
For all statistical analyses, we considered P < .05 as statis-
tically significant. All statistical analyses were performed 
using IBM's SPSS Statistics, version 24.0 for Mac (IBM 
Corporation).
3 |  RESULTS
3.1 | Associations of MMP14 and PROX1 
expression with clinicopathologic variables
Among 278 cases suitable for analysis, 26 (9.4%) had a 
strong, 54 (19.4%) a moderate, and 83 (29.9%) had a weak 
MMP14 expression. No expression was found in 115 (41.4%) 
samples. A high MMP14 expression was associated with an 
older age (P = .041; Table 1).
Over 75% nuclear PROX1 expression was observed in 10 
samples (3.6%), 50% to 75% in 12 samples (4.4%), 25% to 
50% in 28 samples (10.2%), and less than 25% in 71 samples 
(25.8%). Among the 275 cases, in which PROX1 staining 
was interpretable in, nuclear PROX1 expression was absent 
in 154 (56.0%) samples. Positive nuclear PROX1 expression 
was associated with diffuse‐type tumors (P = .041; Table 1) 
and with a high cytoplasmic PROX1 expression (P < .001; 
Table 2). We also found a weak positive correlation between 
the nuclear and cytoplasmic PROX1 expressions (rs = .310; 
P < .001). The association between the nuclear and high cy-
toplasmic PROX1 expressions was examined separately in 
intestinal and diffuse‐type tumors, for which we found strong 
associations in both (Table S1).
T A B L E  1  Association of MMP14 and PROX1 expressions with clinicopathologic variables in 278 gastric cancer patients
 
MMP14a Nuclear PROX1a
Low (%) High (%) P valueb Negative (%) Positive (%) P valueb
Age, y
<67 106 (76.8) 32 (23.2) .041 81 (59.1) 56 (40.9) .298
≥67 92 (65.7) 48 (34.3)   73 (52.9) 65 (47.1)  
Gender
Male 103 (75.7) 33 (24.3) .104 77 (57.0) 58 (43.0) .734
Female 95 (66.9) 47 (33.1)   77 (55.0) 63 (45.0)  
Stage
I 39 (76.5) 12 (23.5) .821 22 (44.0) 28 (56.0) .254
II 46 (70.8) 19 (29.2)   36 (55.4) 29 (44.6)  
III 72 (69.9) 31 (30.1)   63 (61.2) 40 (38.8)  
IV 40 (69.0) 18 (31.0)   32 (57.1) 24 (42.9)  
Tumor classification (pT)
pT1 33 (80.5) 8 (19.5) .251 17 (42.5) 23 (57.5) .312
pT2 31 (77.5) 9 (22.5)   24 (60.0) 16 (40.0)  
pT3 56 (65.1) 30 (34.9)   50 (58.8) 35 (41.2)  
pT4 78 (70.3) 33 (29.7)   63 (57.3) 47 (42.7)  
Lymph node metastasis (pN)
pN0 63 (70.8) 26 (29.2) .969 45 (51.1) 43 (48.9) .304
pN1‐3 127 (70.6) 53 (29.4)   104 (57.8) 76 (42.2)  
Distant metastasis (pM)
M0 158 (71.8) 62 (28.2) .669 122 (55.7) 97 (44.3) .847
M1 40 (69.0) 18 (31.0)   32 (57.1) 24 (42.9)  
Laurén classification
Intestinal 81 (72.3) 31 (27.7) .740 71 (63.4) 41 (36.6) .041
Diffuse 117 (70.5) 49 (29.5)   83 (50.9) 80 (49.1)  
Abbreviations: MMP14, matrix metalloproteinase 14; PROX1, prospero homeobox protein 1.
aBy immunohistochemistry. 
bPearson chi‐squared test. 
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3.2 | Survival analyses
Five‐year disease‐specific survival for gastric cancer patients 
with a low MMP14 expression was 45.3% (95% CI 38.0‐52.6), 
whereas for patients with a high MMP14 it was 35.9% (95% 
CI 24.9‐46.9; P = .030; Figure 2A). Gastric cancer patients 
with a high MMP14 expression had a hazard ratio (HR) of 
1.43 (95% CI 1.03‐1.98; P = .031; Table 3) for the disease‐
specific survival. Nuclear PROX1 expression did not emerge 
as a significant prognostic factor (Figure 2B; Table 3).
In the subgroup analyses, a high MMP14 expression 
emerged as a marker of a worse prognosis among patients 
with negative nuclear PROX1 expression (Figure 2C) and 
among those with a low cytoplasmic PROX1 expression 
(Figure 2D), but not among patients with a positive nuclear 
PROX1 expression (Figure 2E), a high cytoplasmic PROX1 
expression (Figure 2F), intestinal‐ (Figure 2G) or diffuse‐type 
tumors (Figure 2H; Table 4). In addition, a high MMP14 level 
indicated a worse prognosis among patients with pT3 tumors, 
among those with lymph node metastases, and among those 
without distant metastases (Table 4).
Furthermore, a positive nuclear PROX1 expression served 
as a marker of a better prognosis in men (Table 4). We found 
a significantly better prognosis among patients with high cy-
toplasmic and positive nuclear PROX1 expressions (HR 0.45; 
95% CI 0.26‐0.78; P = .004). Among patients with high cyto-
plasmic and positive nuclear PROX1 expressions, 5‐year sur-
vival was 68.6% (95% CI 54.1‐83.5), whereas among patients 
with low cytoplasmic and no nuclear PROX1 expressions 5‐
year survival fell to 37.9% (95% CI 31.2‐44.6; P = .003).
3.3 | Immunofluorescence, immunoblot, and 
siRNA transfection analyses
PROX1 was recently shown to suppress MMP14 expres-
sion in breast cancer, as well as hepatocellular and colorectal 
carcinoma; here we showed that survival is worse specifically 
among those gastric cancer patients with a high MMP14 and 
a low PROX1 expression.21 To further explore the connec-
tion between MMP14 and PROX1 in gastric cancer, we pro-
ceeded by studying the expression levels in cell lines. Cell 
lines, intestinal MKN‐7, intestinal MKN‐28, diffuse TMK‐1, 
and AGS (unknown histological type) were studied using 
immunofluorescence (Figure 3A). In MKN‐7 and AGS, a 
weak MMP14 expression was observed, while in MKN‐28 
and TMK‐1 expression was stronger. In MKN‐7, MKN‐28, 
and TMK‐1, PROX1 expression was very weak, but stronger 
in AGS. In these cell lines, MMP14 was expressed peri-
nuclearly and on the cell surface, whereas PROX1 expres-
sion was nuclear. Variable levels of MMP14 expression in 
MKN‐7, MKN‐28, and TMK‐1 accompanied by a nearly 
absent PROX1 expression may indicate a functional connec-
tion between MMP14 and PROX1 in gastric cancer as well, 
although in AGS both MMP14 and PROX1 were expressed.
In addition, we studied gastric cancer cells using the 
immunoblot analysis (Figure 3B). The predicted molecu-
lar weight for PROX1 is 83  kDa, whereas for MMP14 it 
is 66  kDa. Among the intestinal‐type cell lines, MMP14 
was expressed in MKN‐28 and MKN‐7, in which PROX1 
was not expressed. Furthermore, in the MKN‐74 cells, 
PROX1 was expressed while MMP14 expression was ab-
sent, supporting the inverse correlation in their expression 
as recently demonstrated by Gramolelli et al.21 Among the 
diffuse cell lines, OCUM‐2MD3 cells expressed PROX1, 
but not MMP14, whereas the NUGC3 and MKN‐45 cells 
expressed MMP14, but lacked the PROX1 expression. In 
the KATOIII cells, PROX1 was strongly expressed and 
MMP14 expression was lower than in MKN‐7, MKN‐28, 
NUGC3, and MKN‐45, further supporting the negative 
regulation of MMP14 by PROX1. In the gastric adenocar-
cinoma cell line, AGS, MMP14, and PROX1 were both 
T A B L E  2  Association between MMP14 and PROX1 expressions in 278 gastric cancer patients
 
MMP14a Nuclear PROX1a
Low (%) High (%) P valueb Negative (%) Positive (%) P valueb
Serum MMP14
Low 127 (70.9) 52 (29.1) .804 92 (52.3) 84 (47.7) .273
High 27 (73.0) 10 (27.0)   23 (62.2) 14 (37.8)  
Cytoplasmic PROX1a
Low 153 (71.5) 61 (28.5) .992 137 (64.6) 75 (35.4) <.001
High 40 (71.4) 16 (28.6)   15 (26.8) 41 (73.2)  
Nuclear PROX1a
Negative 109 (71.2) 44 (28.8) .904      
Positive 87 (71.9) 34 (28.1)        
Abbreviations: MMP14, matrix metalloproteinase 14; PROX1, prospero homeobox protein 1.
aBy immunohistochemistry. 
bPearson chi‐squared test. 
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expressed, but did not show clear inverse expression levels. 
In the OCUM‐14 cells, MMP14 and PROX1 were both very 
weakly expressed. The OCUM‐12 or TMK‐1 cells expressed 
neither PROX1 nor MMP14. In total, seven out of eleven 
gastric cancer cell lines—MKN‐28, KATOIII, MKN‐7, 
MKN‐74, MKN‐45, NUGC3, and OCUM‐2MD3—showed 
a clear inverse correlation with the MMP14 and PROX1 
expression levels.
To further explore the functional connection between 
MMP14 and PROX1 in gastric cancer, we silenced PROX1 
in the AGS cells using two different siRNAs. Compared to 
the control siRNA‐treated cells, using both PROX1‐targeting 
siRNAs we achieved an efficient reduction in the PROX1 
level (76% and 69%, respectively), while the MMP14 pro-
tein levels increased by 2.01‐ and 1.85‐fold, respectively, as 
shown by immunoblotting (Figure 3C).
4 |  DISCUSSION
In this study, we confirm that survival is worse among gastric 
cancer patients with a high MMP14 tissue expression and, for 
the first time, show that survival is worse particularly when 
PROX1 is low. We also found that nuclear PROX1 expression 
F I G U R E  2  Disease‐specific survival 
of gastric cancer patients according to the 
Kaplan‐Meier method. A, Low versus high 
matrix metalloproteinase 14 (MMP14) 
expression. B, Negative vs positive nuclear 
prospero homeobox protein 1 (PROX1) 
expression. Low vs high MMP14 expression 
among patients with (C) a negative nuclear 
PROX1 expression, (D) a low cytoplasmic 
PROX1 expression, (E) a positive nuclear 
PROX1 expression, (F) a high cytoplasmic 
PROX1 expression, (G) intestinal‐type, and 
(H) diffuse‐type tumors. P value calculated 
using the log‐rank test
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in gastric cancer tissue samples associates with diffuse‐type 
tumors. In addition, by including data from a previous study of 
cytoplasmic PROX1 expression in gastric cancer tissue sam-
ples from the same patient cohort, we discovered that 5‐year 
disease‐specific survival among patients with positive nuclear 
and high cytoplasmic expressions reached nearly 70%.18
Our results agree with previous studies of MMP14 in 
gastric cancer and provide further validation that survival 
is worse among gastric cancer patients with a high tissue 
MMP14 expression.5,9,10 Here, survival was worse particu-
larly among patients with lymph node‐metastases, no distant 
metastases, pT3 tumors, and importantly, among patients 
with either no nuclear or low cytoplasmic PROX1 immu-
noreactivity. This supports the prominent role played by 
MMP14 in cancer metastasis indicating that a low or absent 
PROX1 expression may be required for MMP14 to be highly 
expressed. This finding agrees with the previously described 
suppressive role of PROX1 on MMP14 transcription.21
PROX1 was recently shown to regulate the transcription 
of MMP14 in multiple cellular contexts; however, gastric 
cancer cases were not included in that study.21 Here, we ex-
plored the connection between PROX1 and MMP14 in gas-
tric cancer, revealing inversely correlated expression levels 
in seven of the eleven cell lines studied, suggesting that the 
PROX1‐MMP14 regulatory axis may also be functional in 
gastric cancer. Additionally, in the immunofluorescence 
analysis, the MMP14 expression in MKN‐7 and MKN‐28 
accompanied by a nearly absent PROX1 expression may 
indicate a functional connection between MMP14 and 
PROX1 in gastric cancer as well. In the AGS cells, how-
ever, MMP14 and PROX1 co‐expressed, indicating that 
other PROX1‐independent mechanisms may also be in-
volved. We then silenced PROX1 in the AGS cells to fur-
ther explore the connection between MMP14 and PROX1 
in gastric cancer, finding that siRNA transfection using two 
PROX1‐targeting siRNAs resulted in increased MMP14 
protein levels in both cases. This further indicates that 
PROX1 participates in governing the MMP14 expression in 
gastric cancer as well.
Few studies of PROX1 in gastric cancer have been 
published, reporting inconsistent results, showing that it 
is highly expressed in cancer compared to healthy tissue 
and associates with a worse although paradoxically with 
a better patient prognosis.17-20 On the one hand, Ueta et 
al20 concluded that nuclear PROX1 expression associates 
with a worse prognosis. On the other hand, Laitinen et al18 
found that cytoplasmic PROX1 expression associated with 
a better prognosis. Here we focused on the nuclear PROX1 
expression, since PROX1 acts as a transcription factor. We 
found no significant association between nuclear PROX1 
expression and survival in the entire patient cohort; how-
ever, when combining the results of nuclear PROX1 
 
Univariate survival analysis Multivariate survival analysis
HR 95% CI P value HR 95% CI P value
Age, y
<67 1.00     1.00    
≥67 1.33 1.00‐1.79 .054 2.50 1.79‐3.48 <.001
Stage
I 1.00     1.00    
II 5.44 2.25‐13.1 <.001 4.51 1.72‐11.9 .002
III 15.7 6.85‐36.1 <.001 16.6 6.67‐41.1 <.001
IV 46.2 19.6‐109 <.001 62.8 24.4‐161 <.001
Laurén classification
Intestinal 1.00     1.00    
Diffuse 1.45 1.06‐1.98 .020 1.62 1.16‐2.27 .005
MMP14a
Low 1.00     1.00    
High 1.43 1.03‐1.98 .031 1.31 0.94‐1.82 .110
Nuclear PROX1a
Negative 1.00          
Positive 0.80 0.58‐1.09 .160      
Abbreviations: CI, confidence interval; HR, hazard ratio; MMP14, matrix metalloproteinase 14; PROX1, 
prospero homeobox protein 1.
aBy immunohistochemistry. 
T A B L E  3  Uni‐ and multivariate 
survival analyses for gastric cancer patients 
according to the Cox proportional hazards 
model
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expression to previous results on cytoplasmic PROX1 ex-
pression, we found that taking nuclear PROX1 expression 
into account strengthens the association of PROX1 tissue 
expression with a better prognosis. This stands in contrast 
to the oncogenic role of PROX1 previously found in gastric 
cancer and with the presumed connection between the nu-
clear PROX1 expression and a worse prognosis. To clarify 
whether cytoplasmic PROX1 merely originates from the 
nucleus or if it has some distinct extra‐nuclear function in 
gastric cancer, further research is necessary.
 
High MMP14a Positive nuclear PROX1a
HR 95% CI P value HR 95% CI P value
Age, y
<67 1.56 0.95‐2.56 .081 0.63 0.39‐1.02 .060
≥67 1.23 0.80‐1.90 .349 0.94 0.61‐1.44 .775
Gender
Male 1.55 0.95‐2.54 .082 0.61 0.38‐0.98 .043
Female 1.33 0.86‐2.06 .196 1.02 0.67‐1.56 .930
Stage
I 0.93 0.10‐8.31 .947 1.36 0.23‐8.15 .738
II 1.73 0.77‐3.90 .185 0.96 0.42‐2.09 .870
III 1.39 0.87‐2.23 .166 0.84 0.53‐1.32 .448
IV 1.25 0.70‐2.25 .447 0.98 0.56‐1.72 .938
Tumor classification (pT)
pT1 1.65 0.17‐15.9 .666 2.43 0.25‐23.4 .442
pT2 0.55 0.12‐2.53 .443 0.71 0.21‐2.36 .576
pT3 1.74 1.04‐2.92 .036 0.60 0.35‐1.03 .066
pT4 1.03 0.65‐1.64 .892 1.07 0.70‐1.64 .763
Lymph node metastasis (pN)
pN0 1.63 0.74‐3.55 .223 0.47 0.21‐1.06 .068
pN1‐3 1.52 1.06‐2.20 .025 1.02 0.71‐1.45 .931
Distant metastasis (pM)
pM0 1.51 1.02‐2.23 .042 0.74 0.50‐1.08 .116
pM1 1.25 0.70‐2.25 .447 0.98 0.56‐1.72 .938
Laurén classification
Intestinal 1.37 0.77‐2.43 .286 0.72 0.40‐1.29 .266
Diffuse 1.44 0.97‐2.14 .072 0.76 0.52‐1.12 .165
MMP14a
Low       0.89 0.60‐1.30 .538
High       0.67 0.39‐1.18 .166
Serum MMP14
Low 1.42 0.94‐2.15 .099 0.77 0.51‐1.15 .200
High 1.42 0.63‐3.23 .401 0.83 0.39‐1.79 .637
Cytoplasmic PROX1a
Low 1.53 1.07‐2.18 .020 1.03 0.72‐1.46 .889
High 1.19 0.48‐2.91 .711 0.60 0.25‐1.43 .247
Nuclear PROX1a
Negative 1.65 1.09‐2.51 .019      
Positive 1.21 0.71‐2.06 .487      
Abbreviations: CI, confidence interval; HR, hazard ratio; MMP14, matrix metalloproteinase 14; PROX1, 
prospero homeobox protein 1
aBy immunohistochemistry. 
T A B L E  4  Survival analyses by 
subgroups for gastric cancer patients 
according to the Cox proportional hazards 
model
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The strengths of this study include the large patient co-
hort with reliable follow‐up information, validation of pre-
vious results, and the exploration of the roles of MMP14 
and PROX1 in gastric cancer in both laboratory and clinical 
settings. More extensive laboratory experiments and analy-
sis on other large, well‐defined patient cohorts are needed 
to further disentangle the functions and cross talk between 
MMP14 and PROX1 in gastric cancer. Since this study was 
carried out retrospectively and, thus, accessing patient de-
tails may introduce inaccuracies, certain well‐known risk 
factors in gastric cancer, such as venous and perineural 
invasion and lymphatic emboli, were not included in our 
analyses.
In conclusion, this study confirms that a high MMP14 ex-
pression predicts worse survival in gastric cancer and, for the 
first time, shows that survival is worse if PROX1 specifically 
is low.
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